Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

The trial was a tremendous success and showed dramatically lower HIV transmission than with the oral drug." Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

Investing.com -- Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP ...

The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth r ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that demonstrated a 96% reduction in infection risk. The prestigious journal ...